Matching articles for "Lasix ONYU"
In Brief: A Bumetanide Nasal Spray (Enbumyst) for Edema
Enbumyst (Corstasis), a nasal spray formulation of the loop diuretic bumetanide, has been approved by the FDA for (short-term) treatment of edema associated with congestive heart failure, renal disease…
Med Lett Drugs Ther. 2026 Apr 13; 68(1752):62-3 doi:10.58347/tml.2026.1752d
Enbumyst (Corstasis), a nasal spray formulation of the loop diuretic bumetanide, has been approved by the FDA for (short-term) treatment of edema associated with congestive heart failure, renal disease (including nephrotic syndrome), or hepatic disease in adults. It is the first diuretic nasal spray formulation to become available in the US. Bumetanide has been available for years in oral and IV formulations.
In Brief: A Second Subcutaneous Furosemide Infusor (Lasix ONYU) for Heart Failure
The FDA has approved Lasix ONYU (SQ Innovation), a subcutaneous formulation of the loop diuretic furosemide administered via a wearable pump (onbody infusor), for treatment of edema in adults with chronic…
Med Lett Drugs Ther. 2026 Mar 16; 68(1750):47-8 doi:10.58347/tml.2026.1750d
The FDA has approved Lasix ONYU (SQ Innovation), a subcutaneous formulation of the loop diuretic furosemide administered via a wearable pump (onbody infusor), for treatment of edema in adults with chronic heart failure (HF). A similar product, Furoscix , is approved for treatment of edema in chronic HF or chronic kidney disease. Furosemide has been available for years in oral and IV formulations for such use.
